<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Bad journalism intersects with medicine and off-label drug usage</title>
	<atom:link href="http://onthepharm.net/2006/05/off-label-prescription-drug-usage.html/feed" rel="self" type="application/rss+xml" />
	<link>http://onthepharm.net/2006/05/off-label-prescription-drug-usage.html</link>
	<description>Life on the pharm</description>
	<pubDate>Fri, 21 Nov 2008 23:57:23 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.3</generator>
		<item>
		<title>By: OnThePharm &#187; AstraZeneca acquires Cambridge Antibody</title>
		<link>http://onthepharm.net/2006/05/off-label-prescription-drug-usage.html#comment-4</link>
		<dc:creator>OnThePharm &#187; AstraZeneca acquires Cambridge Antibody</dc:creator>
		<pubDate>Wed, 17 May 2006 02:50:05 +0000</pubDate>
		<guid isPermaLink="false">http://onthepharm.net/2006/05/off-label-prescription-drug-usage/#comment-4</guid>
		<description>[...] I suspect that sales will increase markedly over the next 12 months; Humira is a relative newcomer on the market, and it is showing some efficacy in treating a number of autoimmune disorders: Crohn&#8217;s disease, rheumatoid arthritis, and severe psoriasis among them. (Humira is currently only approved for certain forms of arthritis, though doctors are using it for off-label purposes.) Due to its steep cost, insurers are often reluctant to pay for it, though arms can usually be twisted in the form of a prior authorization if nothing else has worked. [...]</description>
		<content:encoded><![CDATA[<p>[...] I suspect that sales will increase markedly over the next 12 months; Humira is a relative newcomer on the market, and it is showing some efficacy in treating a number of autoimmune disorders: Crohn&#039;s disease, rheumatoid arthritis, and severe psoriasis among them. (Humira is currently only approved for certain forms of arthritis, though doctors are using it for off-label purposes.) Due to its steep cost, insurers are often reluctant to pay for it, though arms can usually be twisted in the form of a prior authorization if nothing else has worked. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
